Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects host cells through ACE2 receptors, leading to coronavirus disease (COVID-19)-related pneumonia, while also causing acute myocardial injury and chronic damage to the cardiovascular system. Therefore, particular attention should be given to cardiovascular protection during treatment for COVID-19.
MeSH terms
-
Angiotensin Receptor Antagonists / therapeutic use
-
Angiotensin-Converting Enzyme 2
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Antiviral Agents / adverse effects
-
Betacoronavirus
-
COVID-19
-
Cardiotoxicity
-
Cardiovascular Diseases / complications*
-
Cardiovascular Diseases / virology
-
Cardiovascular System / pathology
-
Cardiovascular System / virology*
-
Coronavirus Infections / complications*
-
Coronavirus Infections / physiopathology*
-
Heart / virology
-
Heart Diseases / virology*
-
Humans
-
Hypertension / complications
-
Hypertension / drug therapy
-
Myocardium / pathology
-
Pandemics
-
Peptidyl-Dipeptidase A / metabolism
-
Pneumonia, Viral / complications*
-
Pneumonia, Viral / physiopathology*
-
Receptors, Virus / antagonists & inhibitors
-
Receptors, Virus / metabolism
-
SARS-CoV-2
Substances
-
Angiotensin Receptor Antagonists
-
Angiotensin-Converting Enzyme Inhibitors
-
Antiviral Agents
-
Receptors, Virus
-
Peptidyl-Dipeptidase A
-
ACE2 protein, human
-
Angiotensin-Converting Enzyme 2